Immunization of children at risk of infection with human immunodeficiency virus

Bulletin of the World Health Organization

Volumn 81, Issue 1, 2003, Pages 61-70

  Moss, William J ^a   Clements, C John ^b   Halsey, Neal A ^a   Feinstone, W Harry ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

BCG vaccine immunology adverse effects; Diphtheria tetanus pertussis vaccine immunology; HIV infections immunology; Measles vaccine immunology; Poliovirus vaccine, Oral immunology; Yellow fever vaccine immunology adverse effects

Indexed keywords

ACELLULAR VACCINE; BCG VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE; MEASLES VACCINE; ORAL POLIOMYELITIS VACCINE; RECOMBINANT HEPATITIS B VACCINE; TETANUS TOXOID; VACCINE; YELLOW FEVER VACCINE;

CHILD HEALTH; HEALTH RISK; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNIZATION; VACCINATION;

ARTICLE; BACTEREMIA; BACTERIAL INFECTION; BCG VACCINATION; DIPHTHERIA; DRUG SAFETY; FISTULA; FLACCID PARALYSIS; HAEMOPHILUS INFLUENZAE TYPE B; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; INFLUENZA VACCINATION; LYMPHADENITIS; MEASLES; MEASLES VACCINATION; PERTUSSIS; POLIOMYELITIS; PRACTICE GUIDELINE; SIDE EFFECT; TETANUS; TETANUS PROPHYLAXIS; TUBERCULOSIS; WORLD HEALTH ORGANIZATION; YELLOW FEVER;

ADOLESCENT; ADULT; BACTERIAL VACCINES; CHILD; CHILD, PRESCHOOL; FEMALE; GUIDELINES; HIV INFECTIONS; HUMANS; IMMUNIZATION PROGRAMS; INFANT; MALE; SAFETY; VIRAL VACCINES; WORLD HEALTH ORGANIZATION;

EID: 0037259604     PISSN: 00429686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (69)

1. World Health Organization. Immunization policy. Geneva: World Health Organization; 1996. WHO document WHO/EPI/GEN/95.03.p. 25-7). Available from: URL: http://whqlibdoc.who.int/hq/1995WHO_EPI_GEN_95.03_-ev.1.pdf
2. de Martino M, Podda A, Galli L, Sinangil F, Mannelli F, Rossi ME, et al. Acellular pertussis vaccine in children with perinatal human immunodeficiency virus-type 1 infection. Vaccine 1997;5:1235-8.
3. Zuccotti GV, Riva E, Flumine P, Locatelli V, Fiocchi A, Tordato G, et al. Hepatitis B vaccination in infants of mothers infected with human immunodeficiency virus. Journal of Pediatrics 1994;125:70-2.
4. Choudhury SA, Peters VB. Responses to hepatitis B vaccine boosters in human immunodeficiency virus-infected children. Pediatric Infectious Disease Journal 1995;14:65-7.
5. Rey D, Krantz V, Partisani M, Achmitt MP, Meyer P, Libbrecht E, et al. Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-1 viral load. Vaccine 2000;18:1161-5.
6. Scolfaro C, Fiammengo P, Balbo L, Madon E, Tovo PA. Hepatitis B vaccination in HIV-1 infected children: double efficacy doubling the paediatric dose. AIDS 1996;10:1169-70
7. Mahoney FJ, Kane M. Hepatitis B vaccine. In: Plotkin SA, Orenstein WA, editors. Vaccines. 3rd ed. Philadelphia: W.B. Saunders Company; 1999. p. 158-82.
8. Gibb D, Spoulou V, Giacomelli A, Griffiths H, Masters J, Misbah S, et al. Antibody responses to Haemophilus influenzae type b and Streptococcus pneumoniaevaccines in children with human immunodeficiency virus infection. Pediatric Infectious Disease Journal 1995;14:129-35.
9. Rutstein RM, Rudy BJ, Cnaan A. Response of human immunodeficiency virus-exposed and -infected infants to Haemophilus influenzae type b conjugate vaccine, Archives of Pediatrics and Adolescent Medicine 1996;150:838-41.
10. Gibb D, Giacomelli A, Masters J, Spoulou V, Ruga E, Griffiths H, et al. Persistence of antibody responses to Haemophilus influenzae type b polysaccharide conjugate vaccine in children with vertically acquired human immunodeficiency virus infection. Pediatric Infectious Disease Journal 1996;15:1097-101.
11. Peters VB, Sood SK. Immunity to Haemophilus influenzae type b after reimmunization with oligosaccharide CRM197 conjugate vaccine in children with human immunodeficiency virus infection. Pediatric Infectious Disease Journal 1997;16:711-3.
12. Read JS, Frasch CE, Rich K, Fitzgerald GA, Clemens JD, Pitt J, et al. The immunogenicity of Haemophilus influenzae type b conjugate vaccines in children born to human immunodeficiency virus-infected women. Pediatric Infectious Disease Journal 1998;17:391-7.
13. Ahmed F, Steinhoff MC, Rodreguez-Barradas MC, Hamilton RG, Musher DM, Nelson KE, et al. Effect of human immunodeficiency virus type 1 infection on the antibody response to a glycoprotein conjugate pneumococcal vaccine: results from a randomized trial. Journal of Infectious Diseases 1996;173:83-90.
14. King JC, Vink PE, Farley JJ, Parks M, Smilie M, Madore D, et al. Comparison of the safety and immunogenicity of a pneumococcal conjugate with a licensed polysaccharide vaccine in human immunodeficiency virus and non-human immunodeficiency virus-infected children. Pediatric Infectious Disease Journal 1996;15:192-6.
15. Kroon FP, van Dissel JT, Ravensbergen E, Nibbering PH, van Furth R. Antibodies against pneumococcal polysaccharides after vaccination in HIV-infected individuals: 5-year follow-up of antibody concentrations. Vaccine 2000;18:524-30.
16. French N, Nakiyingi J, Carpenter LM, Lugada E, Warera C, Moi K, et al. 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet 2000;355:2106-11.
17. Msellati P, Dabis F, Lepage P, Hitimana DG, Van Goethem C, Van de Perre P BCG vaccination and pediatric HIV infection - Rwanda, 1988-1990. Morbidity and Mortality Weekly Report 1991;40:833-6.
18. Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, Fineberg HV, et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 1994;271:698-702.
19. Bhat GJ, Diwan VK, Chintu C, Kabika M, Masona J. HIV, BCG and TB in children: A case control study in Lusaka, Zambia. Journal of Tropical pediatrics 1993;39:219-22.
20. Allen S, Batungwanayo J, Kelinkowske K, Lifson AR, Wolf W, Granich R, et al. Two year incidence of tuberculosis in cohorts of HIV-infected and uninfected urban Rwandan women. American Review of Respiratory Disease 1992;146:1439-44.
21. Marsh BJ, von Reyn CF, Edwards J, Ristola MA, Bartholomew C, Brindle RJ, et al. The risks and benefits of childhood bacille Calmette-Guérin immunization among adults with AIDS. AIDS 1997;11:669-72.
22. Ryder RW, Oxtoby MJ, Mvula M, Batter V, Baende E, Nsa W, et al. Safety and immunogenicity of bacille Calmette-Guérin, diphtheria-tetanus-pertussis, and oral polio vaccines in newborn children in Zaire infected with human immunodeficiency virus type 1. Journal of Pediatrics 1993;122:697-702.
23. Oxtoby MJ, Ryder R, Mvula M, Nsa W, Baende E, Onorato I. Patterns of immunity to measles among African children infected with human immunodeficiency virus. In: Epidemic Intelligence Service Conference; 1989 April 3-5; Atlanta, GA.
24. Krasinski K, Borkowsky W. Measles and measles immunity in children infected with human immunodeficiency virus. JAMA 1989;261:2512-6.
25. Palumbo P, Hoyt L, Demasio K, Oleske J, Connor E. Population-based study of measles and measles immunization in human immunodeficiency virus-infected children. Pediatric Infectious Disease Journal 1992;11:1008-14.
26. Thaithumyanon P, Punnahitananda S, Thisyakorn U, Praisuwanna P, Ruxrungtham K. Immune responses to measles immunization and the impacts on HIV-infected children. Southeast Asian Journal of Tropical Medicine and Public Health 2000;31:658-62.
27. Brena AE, Cooper ER, Cabral HJ, Pelton SI. Antibody response to measles and rubella vaccine by children with HIV infection. Journal of Acquired Immune Deficiency Syndromes 1993;6:1125-9.
28. Frenkel LM, Nielsen H, Garakian A, Cherry JD. A search for persistent measles, mumps and rubella vaccine virus in children with human immunodeficiency type-1 infection. Archives of Pediatrics and Adolescent Medicine 1994;148:57-60.
29. Brunell PA, Vimal V, Sandhu M, Courville TM, Daar E, Israele V. Abnormalities of measles antibody response in human immunodeficiency virus type 1 (HIV-1) infection. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1995;10:540-8.
30. Arpadi SM, Markowitz LE, Baughman AL, Shah K, Adam H, Wiznia A, et al. Measles antibody in vaccinated human immunodeficiency virus type 1-infected children. Pediatrics 1996;97:653-7.
31. Molyneaux PJ, Mok JYQ, Burns SM, Yap PL. Measles, mumps, and rubella immunisation in children at risk of infection with human immunodeficiency virus. Journal of Infection 1993;27:151-3.
32. Rudy BJ, Rutstein RM, Pinto-Martin J. Response to measles immunization in children infected with human immunodeficiency virus. Journal of Pediatrics 1994;125:72-4.
33. Al-Attar I, Reisman J, Muehlmann M, McIntosh K. Decline of measles antibody titres after immunization in human immunodeficiency virus-infected children. Pediatric Infectious Disease Journal 1995;14:149-51.
34. Wallace MR, Hooper DG, Graves SJ, Malone JL. Measles seroprevalence and vaccine response in HIV-infected adults. Vaccine 1994;12:1222-4.
35. Kemper CA, Gangar M, Arias G, Kane C, Deresinski SC. The prevalence of measles antibody in human immunodeficiency virus-infected patients in Northern California. Journal of Infectious Diseases 1998;178:1177-80.
36. Waibale P, Bowlin SJ, Mortimer EA, Whalen C. The effect of human immunodeficiency virus-1 infection and stunting on measles immunoglobulin-G levels in children vaccinated against measles in Uganda. International Journal of Epidemiology 1999;28:341-6.
37. Lepage P, Dabis F, Msellati P, Hitimana DG, Stevens AM, Mukamabano B, et al. Safety and immunogenicity of high-dose Edmonston-Zagreb measles vaccine in children with HIV-1 infection. A cohort study in Kigali, Rwanda. American Journal of Diseases of Children 1992;146:550-5.
38. Embree JE, Datta P, Stackiw W, Sekla L, Braddick M, Kreiss JK, et al. Increased risk of early measles in infants of human immunodeficiency virus type 1-seropositive mothers. Journal of Infectious Diseases 1992;165:262-7.
39. Biellik R, Madema S, Taole A, Kutsulukuta A, Allies E, Eggers R, et al. First 5 years of measles elimination in southern Africa: 1996-2000. Lancet 2002;359:1564-8.
40. Permar SR, Moss WJ, Ryon JJ, Kutsulukuta A, Allies E, Eggers R, et al. Prolonged measles virus shedding in human immunodeficiency virus-infected children, detected by reverse transcriptase-polymerase chain reaction. Journal of Infectious Diseases 2001;183:532-8.
41. Sibailly TS, Wiktor SZ, Tsai TF, Cropp BC, Ekpini ER, Adjorlolo-Johnson G, et al. Poor antibody response to yellow fever vaccination in children infected with human immunodeficiency virus type 1. Infectious Disease Journal 1997;16:1177-9.
42. Goujon C, Touin M, Feuillie V, Coulaud P, Dupont B, Sansonetti P. Good tolerance and efficacy of yellow fever vaccine among carriers of human immunodeficiency virus. Journal of Travel Medicine 1995;2:145.
43. Lotte A, Wasz-Hockert P, Poisson N, Dumitrescu N, Verron M, Couvet E. BCG complications: Estimates of the risks among vaccinated subjects and statistical analysis of their main characteristics. Advances In Tuberculosis Research 1984;21:107-93.
44. O'Brien KL, Ruff AJ, Louis MA, Desormeaux J, Joseph DJ, McBrien M, et al. Bacillus Calmette-Guérin complications in children born to HIV-1-infected women with a review of the literature. Pediatrics 1995;95:414-8.
45. Talbot EA, Perkins MD, Silva SFM, Frothingham R. Disseminated bacille Calmette-Guérin disease after vaccination: case report and review. Clinical Infectious Diseases 1997;24:1139-46.
46. Armbruster C, Junker W, Vetter N, Jaksch G. Disseminated bacille Calmette-Guérin infection in an AIDS patient 30 years after BCG vaccination. Journal of Infectious Diseases 1990;162:1216.
47. Besnard M, Sauvion S, Offredo C, Gaudelus J, Gaillard JL, Veber F, et al. Bacillus Calmette-Guérin infection after vaccination of human immunodeficiency virus-infected children. Pediatric Infectious Disease Journal 1993;12:993-7.
48. Ion-Nedelcu N, Dobrescu A, Strebel PM, Sutter RW. Vaccine-associated paralytic poliomyelitis and HIV infection. Lancet 1994;343:51-2.
49. Chitsike I, van Furth R. Paralytic poliomyelitis associated with live oral poliomyelitis vaccine in child with HIV infection in Zimbabwe: case report. BMJ 1999;318:841-3.
50. Strebel PM, Aubert-Combiescu A, Ion-Nedelcu N, Biberi-Moroeanu S, Combiescu M, Sutter RW, et al. Paralytic poliomyelitis in Romania, 1984-1992. Evidence for a high risk of vaccine-associated disease and reintroduction of wild-virus infection. American Journal of Epidemiology 1994;140:1111-24.
51. Moss WJ, Cutts F, Griffin DE. Implications of the human immunodeficiency virus epidemic for control and eradication of measles Clinical Infectious Diseases 1999;29:106-12.
52. Sprauer MA, Markowitz LE, Nicholson JKA, Holman RC, Deforest A, Dales LG, et al. Response of human immunodeficiency virus-infected adults to measles-rubella vaccination. Journal of Acquired Immune Deficiency Syndromes 1993;6:1013-6.
53. McLaughlin M, Thomas P, Onorato I, Rubinstein A, Oleske J, Nicholas S, et al. Live virus vaccines in human immunodeficiency virus infected children: a retrospective survey. Pediatrics 1988;82:229-33.
54. Goon P, Cohen B, Jin L, Watkins R, Tudor-Williams G. MMR vaccine in HIV-infected children - potential hazards? Vaccine 2001;19:3816-9.
55. Angel JB, Walpita P, Lerch RA, Sidhu MS, Masurekar M, DeLellis RA, et al. Vaccine-associated measles pneumonitis in an adult with AIDS. Annals of Internal Medicine 1998;129:104-6.
56. Kengsakul K, Sathirapongsasuti K, Punyagupta S. Fatal myeloencephalitis following yellow fever vaccination in a case with HIV infection. Journal of the Medical Association of Thailand 2002;85:131-4.
57. Receveur MC, Thiebaut R, Vedy S, Malvy D, Mercie P, Bras ML Yellow fever vaccination of human immunodeficiency virus-infected patients: report of 2 cases. Clinical Infectious Diseases 2000;31:E7-8.
58. Marianneau P, Georges-Courbot M, Deubel V. Rarity of adverse effects after 17D yellow-fever vaccination. Lancet 2001;358:84-5.
59. Glesby MJ, Hoover DR, Farzadegan H, Margolick JB, Saah AJ. The effect of influenza vaccination on human immunodeficiency virus type 1 load: a randomized, double-blind, placebo-controlled study. Journal of Infectious Diseases 1996;174:1332-6.
60. Stanley SK, Ostrowski MA, Justement JS, Gantt K, Hedayati S, Mannix M, et al. Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. New England Journal of Medicine 1996;334:1222-30.
61. Ho DD. DID. HIV-1 viraemia and influenza. Lancet 1992;339:1549.
62. Staprans SI, Hamiltion BL, Follansbee SE, Elbeik T, Barbosa P, Grant RM, et al. Activation of virus replication after vaccination of HIV-1-infected individuals. Journal of Experimental Medicine 1995;182:1727-37.
63. Ramilo O, Hicks PJ, Borvak J, Gross LM, Zhong D, Squires IE, et al. T cell activation and human immunodeficiency virus replication after influenza immunization of infected children. Pediatric Infectious Disease Journal 1996;15:197-203.
64. Tasker SA, O'Brien WA, Treanor JJ, Weiss PJ, Olson PE, Kaplan AH, et al. Effects of influenza vaccination in HIV-infected adults: a double-blind, placebo-controlled trial. Vaccine 1998;16:1039-42.
65. Brichacek B, Swindells S, Janoff EN, Pirruccello S, Stevenson M. Increased plasma human immunodeficiency virus type 1 burden following antigenic challenge with pneumococcal vaccine. Journal of Infectious Diseases 1996;174:1191-9.
66. Keller M, Deveikis A, Cutillar-Garcia M, Gagajena A, Elkins K, Plaeger S, et al. Pneumococcal and influenza immunization and human immunodeficiency virus load in children. Pediatric Infectious Disease Journal 2000;19:613-8.
67. Cheeseman SH, Davaro RE, Ellision, RT. Hepatitis B vaccination and plasma HIV-1 RNA. New England Journal of Medicine 1996;334:1272.
68. Tovo PA, de Martino M, Gabiano C, Galli L. Pertussis immunization in HIV-1-infected infants: a model to assess the effects of repeated T cell-dependent antigen administrations on HIV-1 progression. Italian Register for HIV Infection in Children. Vaccine 2000;18:1203-9.
69. Hyams KC. Risk of chronicity following acute hepatitis B virus infection: a review. Clinical Infectious Diseases 1995;20:992-1000.